AbbVie (ABBV) News Today

AbbVie Inc. (NYSE:ABBV) saw its shares buoyed by clinical and operational milestones, even as some analysts trimmed their outlook. Below is a rundown of today’s key news and how each item may impact investor sentiment.

• Positive Sentiment: Leerink Partners raised its price target on AbbVie, citing robust performance across its portfolio and stronger-than-expected sales momentum Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance
• Positive Sentiment: AbbVie filed a New Drug Application with the FDA for tavapadon, its experimental once-daily oral Parkinson’s therapy based on positive Phase 3 TEMPO trial data AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA
• Positive Sentiment: The company broke ground on a $70 million U.S. biologics manufacturing site to bolster capacity for its growing pipeline AbbVie breaks ground on $70m US biologics site amid Trump pressure
• Positive Sentiment: AbbVie commenced a $70 million expansion of its Massachusetts facility to mitigate upcoming pharmaceutical tariffs and support higher production volumes AbbVie begins $70M Massachusetts expansion as pharmaceutical tariffs kick in
• Positive Sentiment: An expansion project and a regulatory win for a peer biotech drove AbbVie’s shares up nearly 6% intraday, underlining investor appetite for growth catalysts Why AbbVie Stock Cruised to an Almost 6% Gain Today
• Positive Sentiment: Barchart highlighted AbbVie as a standout after the Allergan acquisition, noting fresh all-time highs, a unanimous “Buy” consensus, and trading above key moving averages AbbVie Stock Is Just What the Doctor Ordered
• Positive Sentiment: Natrelle® secured a supplier agreement with Vizient, giving healthcare providers broader access to AbbVie’s leading breast implant portfolio Natrelle® Awarded Supplier Agreement from Vizient
• Neutral Sentiment: A feature on AbbVie’s long history of dividend increases underscored the stock’s appeal to income-oriented investors seeking stability AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability
• Neutral Sentiment: A Benzinga analysis examined AbbVie’s options-trading patterns and open-interest flows to gauge market expectations, without taking a directional stance A Closer Look at AbbVie’s Options Market Dynamics
• Neutral Sentiment: In a broader piece on dividend stocks, The Motley Fool included AbbVie among three S&P 500 names positioned for long-term, passive-income investors Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
• Negative Sentiment: HSBC downgraded AbbVie from “Buy” to “Hold,” citing valuation concerns after the recent rally AbbVie (NYSE:ABBV) Lowered to "Hold" Rating by HSBC
• Negative Sentiment: Bernstein reiterated its “Hold” rating on AbbVie, maintaining a cautious stance on near-term upside amid high expectations Bernstein Reaffirms Their Hold Rating on AbbVie (ABBV)